BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15012612)

  • 1. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.
    Cohen O; Dabhi S; Karasik A; Zila Zwas S
    Eur J Endocrinol; 2004 Mar; 150(3):285-90. PubMed ID: 15012612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
    Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
    Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.
    Montella L; Caraglia M; Abbruzzese A; Soricelli A; Prete SD; Squame G; Salvatore M
    Exp Mol Med; 2004 Jun; 36(3):268-73. PubMed ID: 15272239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin.
    Haugen BR; Ridgway EC; McLaughlin BA; McDermott MT
    Thyroid; 2002 Jan; 12(1):37-43. PubMed ID: 11838729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
    David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
    J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of recombinant human TSH in the diagnostic protocol of differentiated thyroid carcinoma].
    Jiménez-Hoyuela García JM; García Almeida JM; Delgado García A; Aguilar Fernández I; Martínez del Valle Torres MD; Ortega Lozano S; Rebollo Aguirre A; Mancha Doblas I; Pinzón Martín JL; Picón César MJ; Zamorano Vázquez D
    Rev Esp Med Nucl; 2005; 24(3):152-60. PubMed ID: 15847782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.
    Giovanni V; Arianna LG; Antonio C; Francesco F; Michele K; Giovanni S; Marco S; Giovanni L
    Clin Endocrinol (Oxf); 2002 Feb; 56(2):247-52. PubMed ID: 11874417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma].
    Rajkovaca Z; Kovacević P; Stanetić M; Ristić S
    Vojnosanit Pregl; 2012 Nov; 69(11):941-6. PubMed ID: 23311243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
    Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
    Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
    Haugen BR; Pacini F; Reiners C; Schlumberger M; Ladenson PW; Sherman SI; Cooper DS; Graham KE; Braverman LE; Skarulis MC; Davies TF; DeGroot LJ; Mazzaferri EL; Daniels GH; Ross DS; Luster M; Samuels MH; Becker DV; Maxon HR; Cavalieri RR; Spencer CA; McEllin K; Weintraub BD; Ridgway EC
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3877-85. PubMed ID: 10566623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of I-123 and I-131 for whole-body imaging after stimulation by recombinant human thyrotropin: a preliminary report.
    Anderson GS; Fish S; Nakhoda K; Zhuang H; Alavi A; Mandel SJ
    Clin Nucl Med; 2003 Feb; 28(2):93-6. PubMed ID: 12544124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
    Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
    Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
    Podoba J
    Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.